Results 141 to 150 of about 1,254,901 (269)
Physicians' Perceptions of Prescribing in Pregnancy and Package Inserts: A Survey of General and Hub Hospitals in Japan. [PDF]
Goto M, Yakuwa N, Murashima A.
europepmc +1 more source
Florence Nightingale’s Influence on Hospital Design, Hospitalism, Hospital Diseases, and Hospital Architects [PDF]
openaire +2 more sources
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Exploring the Interface Between International Nongovernmental Organizations and Local Vietnamese Hospitals in Cleft Care. [PDF]
Le T +7 more
europepmc +1 more source
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Antibiotic stewardship in hospital outpatient departments: a qualitative study of alignment with existing guidance. [PDF]
Chitavi SO +5 more
europepmc +1 more source
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens +6 more
wiley +1 more source
Enhancing perinatal care in Rwanda: building quality improvement into system strengthening. [PDF]
Tuyisenge L +10 more
europepmc +1 more source
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi +14 more
wiley +1 more source
Maya R Kalogirou, Jennifer Baumbusch School of Nursing, University of British Columbia, Vancouver, BC, CanadaCorrespondence: Maya R Kalogirou, University of Alberta, College of Health Sciences, Faculty of Nursing, Edmonton Clinic Health Academy (ECHA ...
Kalogirou MR, Baumbusch J
doaj

